Back to search

University of Strathclyde

Pharmacological characterisation of small molecule RGD-mimetics targeting ?v?6-mediated activation of TGF? in idiopathic pulmonary fibrosis

Abstract

dc:description.abstract

Fibrosis is the formation of scar tissue due to injury or long-term inflammation and is a leading cause of morbidity and mortality in disorders that include idiopathic pulmonary fibrosis (IPF). The alpha-v beta-6 (?v?6) integrin has been identified as playing a key role in the activation of transforming growth factor-? (TGF?) that is hypothesized to be pivotal in the development of IPF. Therefore, the ?v?6 integrin was identified as an attractive therapeutic target for this debilitating disease and a drug discovery programme to identify inhaled small molecule ?v?6 selective arginylglycinyl- aspartic acid (RGD)-mimetics was initiated within GlaxoSmithKline. The primary aim of this study was to pharmacologically characterise the small molecule ?v?6 RGD-mimetics generated in a range of test systems. RGD ligands including peptides, antibodies and small molecule RGD-mimetics were characterised in vitro using methods that included radioligand binding, cell adhesion, flow cytometry, coculture TGF? bioassays, confocal microscopy and immunohistochemistry. This included the use of soluble recombinant integrin protein, stable and primary cells expressing integrins recombinantly or endogenously and human lung tissue from normal and IPF donors. Compound 3 generated from an internal medicinal chemistry programme was shown to bind to the ?v?6 with high affinity (pM) and displayed fast association with the integrin followed by slow dissociation kinetics in all systems investigated. Using [3H]compound 3 the quantification of the upregulation of ?v?6 from normal to IPF human lung tissue has been determined for the first time with data suggesting ?v?6 exists in a highly activated state within diseased tissue. In human lung primary epithelial cells co-cultured with a TGF? reporter cell system, compound 3 was shown to inhibit with high potency the activation of TGF? with a prolonged duration of action. In the same primary lung epithelial cells compound 3 caused a rapid internalisation of ?v?6 (minutes) followed by a slow return of the integrin to the cell surface (hours). It was shown that ?v?6 is degraded in lysosomes post-internalisation by compound 3 that would suggest the slow return of integrin to the surface and sustained duration of action is a consequence of new ?v?6 synthesis. From the chemical series of small molecule RGD-mimetic compounds identified, compound 3 has been shown to display the desirable pharmacological characteristics required for targeting a prolonged inhibition of TGF? activation in the IPF lung via blockade of the ?v?6 integrin.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral-pg
Grantor dc:publisher.institution
University of Strathclyde
Year dc:date.issued
2015

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Slack, Robert J.
Advisors dc:contributor.advisor
  • Pyne, Susan
  • Denyer, Jane
  • Flint, David
Author Identifier dc:creator.authoridentifier
  • 201287345

Rights

Identifiers

dc:identifier.*
Identifier
T16064

Chain of custody

source
Harvested from
University of Strathclyde
Base URL
stax.strath.ac.uk/catalog/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Slack, Robert J.. Pharmacological characterisation of small molecule RGD-mimetics targeting ?v?6-mediated activation of TGF? in idiopathic pulmonary fibrosis. doctoral-pg thesis, University of Strathclyde, 2015. https://stax.strath.ac.uk/concern/theses/73666483h